A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes
NCT ID: NCT00050843
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
220 participants
INTERVENTIONAL
2001-08-31
2004-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
thalidomide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must be able to adhere to the study visit schedule and other protocol requirements.
* Patients must understand and voluntarily sign an informed consent document.
* Women of childbearing potential (WCBP) must agree to practice abstinence or to use TWO methods of contraception beginning 4 weeks prior to the start of study medication and throughout the course of treatment.
* Males must use barrier contraception when engaging in reproductive sexual activity with women of childbearing potential.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene Corporation
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Scripps Cancer Center
La Jolla, California, United States
Comprehensive Cancer Centers of the Desert
Palm Springs, California, United States
Desert Hematology Oncology Medical Group INC
Rancho Mirage, California, United States
Whittingham Cancer Center
Norwalk, Connecticut, United States
VA Connecticut Healthcare System
West Haven, Connecticut, United States
Southeast Florida Hematology-Oncology
Fort Lauderdale, Florida, United States
Florida Cancer Specialists
Fort Myers, Florida, United States
Northwest Medical Specialists
Arlington Heights, Illinois, United States
Oncology Associates
Cedar Rapids, Iowa, United States
Beaumont Cancer Center
Royal Oak, Michigan, United States
SMDC Health Systems
Duluth, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
Jackson Oncology Associates PLLC
Jackson, Mississippi, United States
Hematology Oncology Consultants Inc
St Louis, Missouri, United States
Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, United States
Hematology Oncology Associates of NJ
Paramus, New Jersey, United States
Summit Medical Group/Overlook Oncology Center
Summit, New Jersey, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Memorial Sloan Kettering Cancer Ctr
New York, New York, United States
VAMC Northport
Northport, New York, United States
University of Rochester Cancer Center
Rochester, New York, United States
South Shore Hem-Onc Assoc. PA
Rockville Centre, New York, United States
Staten Island Unversity Hospital
Staten Island, New York, United States
Westchester County Medical Center
Valhalla, New York, United States
Buffalo Medical Group PC
Williamsville, New York, United States
Northwestern Carolina Hematology Oncology PA
Hickory, North Carolina, United States
Wake Forest Univ School of Medicine
Winston-Salem, North Carolina, United States
Oncology/Hematology Care Inc
Cincinnati, Ohio, United States
Oregon Health & Science University
Portland, Oregon, United States
Medical Oncology Associates
Kingston, Pennsylvania, United States
Lancaster Cancer Center LTD
Lancaster, Pennsylvania, United States
MCP Hahnemann University
Philadelphia, Pennsylvania, United States
Western Pennsylvania Cancer Institute
Pittsburgh, Pennsylvania, United States
Texas Oncology PA-BMT Center
Dallas, Texas, United States
Central Utah Medical Clinic
Provo, Utah, United States
InterMountain Hematology/Oncology
Salt Lake City, Utah, United States
Swedish Cancer Institute
Seattle, Washington, United States
Yakima Regional CancerCenter
Yakima, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
THAL-MDS-001
Identifier Type: -
Identifier Source: org_study_id